Lipidated IL-22 Alone or Combined with Immunomodulatory Agents Improves Disease Endpoints and Promotes Mucosal Healing in a Mouse Model of Chronic Dextran Sodium Sulfate-Induced Colitis

• DOI: 10.1007/s10620-025-09007-w
• Publication Date: 2025-03-29T08:27:06Z
• Authors: Sidsel Støy; Silvia D’Alessio; Thomas Damgaard S...; Anders Dige; Anne Louise Kjølbye; Rasmus Jorgensen; Silvio Danese; Martijn van de Bunt
• Keywords: Transplant surgery

IL-22 facilitates mucosal healing by directly inducing epithelial regeneration and barrier integrity, which is essential for achieving remission thereby treating inflammatory bowel disease. Here, we evaluated efficacy of a novel lipidated alone in combination with immunomodulatory agents addressing chronic dextran sodium sulfate (DSS)-induced colitis mice demonstrated action on healing. Mice were treated DSS, followed various doses IL-22, anti-TNF antibody, fingolimod, or anti-mouse α4β7 integrin antibody. Additionally, gene expression was determined colonic biopsies from ulcerative patients to assess effects stimulation. Lipidated significantly improved all aspects DSS-induced mice, dose-dependent efficacy. Combinations range showed further additive reductions disease activity, greater than those monotherapies. Immunohistochemistry revealed that increased cell proliferation reduced CD3+ T-cell infiltration, indicating enhanced This supported data after Given the challenges long-term IBD due inflammation damage, presents promising treatment option promotes healing, unlike traditional therapies.